Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSIGHT: Toripalimab and Induction Chemotherapy for Larynx Preservation
NCT04995120Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Apr 2021
- Primary completion
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in laryngeal squamous cell carcinoma (LSCC), hypopharyngeal squamous cell carcinoma (HSCC), sponsored by Fudan University. Started Apr 2021; status: recruiting.
02
Drugs
toripalimab
03
Conditions
laryngeal squamous cell carcinoma (LSCC)hypopharyngeal squamous cell carcinoma (HSCC)
Beyond the preview
Go deeper on NCT04995120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04995120.